Page 679 - Basic _ Clinical Pharmacology ( PDFDrive )

CHAPTER 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout 665

Ray WA et al: COX-2 selective non-steroidal anti-inflammatory drugs and risk of Griffiths CE et al: Comparison of ustekinumab and etanercept for moderate-to-
serious coronary heart disease. Lancet 2002;360:1071. severe psoriasis. N Engl J Med 2010;362:118.
Rovensky J et al: Treatment of knee osteoarthritis with a topical nonsteroidal Keystone E et al: Improvement in patient-reported outcomes in a rituximab trial
anti-inflammatory drug. Results of a randomized, double-blind, placebo- in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis
controlled study on the efficacy and safety of a 5% ibuprofen cream. Drugs factor therapy. Arthritis Rheum 2008;59:785.
Exp Clin Res 2001;27:209. Khanna D et al: Safety and efficacy of subcutaneous tocilizumab in adults with
Slawson D: NSAID Use associated with increased risk of serious bleeding and CV systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.
events after MI. Am Fam Physician 2015;92;60. Lancet 2016;387:2630.
U.S. Food and Drug Administration: FDA Drug Safety Communication: FDA Kobayashi K et al: Leukoencephalopathy with cognitive impairment following
strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs tocilizumab for the treatment of rheumatoid arthritis (RA). Intern Med
(NSAIDs) can cause heart attacks or strokes. Available at: www.fda.gov/ 2009;48:15.
Drugs/DrugSafety/ucm451800.htm. Kremer J: Toward a better understanding of methotrexate. Arthritis Rheum
Vane J, Botting R: Inflammation and the mechanism of action of anti- 2004;50:1370.
inflammatory drugs. FASEB J 1987;1:89. http://www.rheumatology. Landewé R et al: Efficacy of certolizumab pegol on signs and symptoms of axial
org/I-Am-A/Patient-Caregiver/Treatments/NSAIDs. spondyloarthritis including ankylosing spondylitis: 24-week results of a
double-blind randomised placebo-controlled Phase 3 study. Ann Rheum
Disease-Modifying Antirheumatic Drugs & Glucocorticoids Dis 2014;73:1.
Maurizio Cutolo: The kinase inhibitor tofacitinib in patients with rheumatoid
Atzeni F et al: Potential target of infliximab in autoimmune and inflammatory arthritis: Latest findings and clinical potential. Ther Adv Musculoskelet Dis
diseases. Autoimmun Rev 2007;6:8. 2013;5:1.
Bannwarth B, Kostine M, Poursac N: A pharmacokinetic and clinical assessment Mease P et al: Abatacept in the treatment of patients with psoriatic arthritis: results
of tofacitinib for the treatment of rheumatoid arthritis. Expert Opin Drug of a double-blind, randomized, placebo-controlled phase 2 trial. Arthritis
Metab Toxicol 2013;9:6. Rheum 2011;63:939.
Besada E, Koldingsnes W, Nossent J: Characteristics of late onset neutropenia in Mease PJ et al: Effect of certolizumab pegol on signs and symptoms in patients
rheumatologic patients treated with rituximab: A case review analysis from a with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised
single center. QJM 2012;105:6. placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014;73:1.
Bongartz T et al: Anti-TNF antibody therapy in rheumatoid arthritis and the risk Nadashkevich O et al: A randomized unblinded trial of cyclophosphamide versus
of serious infections and malignancies. JAMA 2006;295:2275. azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006;25.
Bosello S et al: B cell depletion in diffuse progressive systemic sclerosis: safety, Ørum M et al: Beneficial effect of infliximab on refractory sarcoidosis. Dan Med
skin score modification and IL-6 modulation in an up to thirty-six months J 2012;59:12.
follow-up open-label trial. Arthritis Res Ther 2010;12:R54. Papoutsaki M et al: Infliximab in psoriasis and psoriatic arthritis. BioDrugs
Conklyn M et al: The JAK3 inhibitor CP-690550 selectively reduces NK and 2013;27(Suppl 1):13.
CD8+ cell numbers in cynomolgus monkey blood following chronic oral Plosker G, Croom K: Sulfasalazine: A review of its use in the management of
dosing. J Leukoc Biol 2004;76:6. rheumatoid arthritis. Drugs 2006;65:1825.
Cronstein B: How does methotrexate suppress inflammation? Clin Exp Rheumatol Riese RJ, Krishnaswami S, Kremer J: Inhibition of JAK kinases in patients with
2010:28(Suppl 61):S21. rheumatoid arthritis: Scientific rationale and clinical outcomes. Best Pract
De Lauretis A et al: Serum interleukin 6 is predictive of early functional decline Res Clin Rheumatol 2010;24:4.
and mortality in interstitial lung disease associated with systemic sclerosis. Ruperto N et al: Abatacept in children with juvenile idiopathic arthritis: a ran-
J Rheumatol 2013;40:435. domised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;
Dinarello CA, Simon A, van der Meer JW: Treating inflammation by block- 2:372.
ing interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov Scott DL, Kingsley GH: Tumor necrosis factor inhibitors for rheumatoid arthritis.
2012;11:8. N Engl J Med 2006;355:704.
Emery P et al: Golimumab, a human anti-tumor necrosis factor α monoclonal Shima Y et al: The skin of patients with systemic sclerosis softened during the
antibody, injected subcutaneously every four weeks in methotrexate-naïve treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology
patients with active rheumatoid arthritis. Arthritis Rheum 2009;60:2272. (Oxford) 2010;49:2408.
Emery P et al: IL-6 receptor inhibition with tocilizumab improves treatment Smolen J et al: Efficacy and safety of certolizumab pegol plus methotrexate in
outcomes in patients with rheumatoid arthritis refractory to anti-tumour active rheumatoid arthritis: the RAPID 2 study. A randomized controlled
necrosis factor biologicals: results from a 24-week multicentre randomized trial. Ann Rheum Dis 2009;68:797.
placebo-controlled trial. Ann Rheum Dis 2008;67:1516. Spies CM et al: Prednisone chronotherapy. Clin Exp Rheumatol 2011;
Emery P et al: The impact of T-cell co-stimulation modulation in patients with 29(Suppl 68):5.
undifferentiated inflammatory arthritis or very early rheumatoid arthritis:
a clinical and imaging study of abatacept. Ann Rheum Dis 2010;69:510. Strober B et al: Effect of tofacitinib, a Janus kinase inhibitor, on haemato-
logical parameters during 12 weeks of psoriasis treatment. Br J Dermatol
Feagan BG et al: The effects of infliximab therapy on health-related quality of life 2013;169:5.
in ulcerative colitis patients. Am J Gastroenterol 2007;102:4. Tanaka T, Ogata A, Narazaki M: Tocilizumab for the treatment of rheumatoid
Fleischmann R et al: Review of head-to-head study designs in rheumatoid arthritis. arthritis. Expert Rev Clin Immunol 2010;6:6.
Semin Arthritis Rheum 2016;46:279. Teng GG, Turkiewicz AM, Moreland LW: Abatacept: A costimulatory inhibitor
Furst DE: Rational use of disease-modifying antirheumatic drugs. Drugs for treatment of rheumatoid arthritis. Expert Opin Biol Ther 2005;5:1245.
1990;39:19. Turner D: Severe acute ulcerative colitis: the pediatric perspective. Dig Dis
Furst DE et al: Updated consensus statement on biological agents for the treatment 2009;27:3
of rheumatic diseases, 2012. Ann Rheum Dis 2013;72. van Gurp EA et al: The effect of the JAK inhibitor CP-690,550 on peripheral
Gabay C et al: Tocilizumab monotherapy versus adalimumab monotherapy for immune parameters in stable kidney allograft patients. Transplantation
treatment of rheumatoid arthritis (ADACTA): A randomised, double-blind, 2009;87:1.
controlled phase 4 trial. Lancet 2013;4:381. Weinblatt M et al: Adalimumab, a fully human anti-tumor necrosis factor α
Genovese MC et al: Abatacept for rheumatoid arthritis refractory to tumor necrosis monoclonal antibody, for the treatment of rheumatoid arthritis in patients
factor α inhibition. N Engl J Med 2005;353:1114. taking concomitant methotrexate. Arthritis Rheum 2003;48:35.
Genovese MC et al: Subcutaneous abatacept versus intravenous abatacept: A Weinblatt ME et al: Head-to-head comparison of subcutaneous abatacept versus
phase IIIb noninferiority study in patients with an inadequate response to adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multina-
methotrexate. Arthritis Rheum 2011;63:10. tional, prospective, randomized study. Arthritis Rheum 2013;65:1.